Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822962 | 0.96 | RAB9A (0.45) | RAB9ASMN1; SMN2NPSR1EPHX2HPGDS | |
| SCHEMBL2825405 | 0.80 | HCRTR1 (0.48) | EPHX2SCD | |
| SCHEMBL2820646 | 0.76 | SMO (0.49) | RAB9ASMN1; SMN2NPSR1HPGDSSCD | |
| SCHEMBL13282316 | 0.74 | RBP4 (0.52) | RAB9ASMN1; SMN2NPSR1EPHX2SCD | |
| SCHEMBL2820795 | 0.73 | PDGFRB (0.46) | SMN1; SMN2NPSR1HPGDSSCDNPY2R | |
| SCHEMBL13536495 | 0.72 | HCRTR1 (0.47) | EPHX2SCDNPY2R | |
| SCHEMBL2821695 | 0.71 | HCRTR1 (0.50) | SMN1; SMN2SCD | |
| SCHEMBL2821972 | 0.71 | TRPV1 (0.44) | SCD | |
| SCHEMBL2820773 | 0.69 | HCRTR1 (0.48) | SMN1; SMN2EPHX2SCD | |
| SCHEMBL2821970 | 0.68 | MGLL (0.58) | SCDNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | RAB9A 4065/4885SMN1; SMN2 4076/4885NPSR1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.